BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant. The Accompanying Warrants have an exercise price of $1.614 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance. The Company also reduced the exercise price of warrants to purchase up to an agg
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.GlobeNewswire
- BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
- How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics (BTAI) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
BTAI
Earnings
- 11/12/25 - Miss
BTAI
Sec Filings
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- BTAI's page on the SEC website